A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2021-10-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seagen Inc.; Seattle Genetics, Inc.
• Collaborator: Bristol-Myers Squibb
• Treatments: Antibodies; Antibodies, Monoclonal; Brentuximab Vedotin; Nivolumab

Criteria

Inclusion Criteria:

• Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

• Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant

• Documented history of a cerebral vascular event

• History of another invasive malignancy that has not been in remission for at least 3 years

• History of progressive multifocal leukoencephalopathy (PML)